Ruyu Yan, Megan Kurz, B Carolina Guerra-Alejos, Jeong Eun Min, Paxton Bach, Sander Greenland, Paul Gustafson, Ehsan Karim, P Todd Korthuis, Tom Loughin, Lawrence McCandless, Robert W Platt, Kevin Schnepel, Shaun Seaman, M Eugenia Socías, Evan Wood, Hui Xie, Bohdan Nosyk
INTRODUCTION: Opioid agonist treatment (OAT) tapering involves a gradual reduction in daily medication dose to ultimately reach a state of opioid abstinence. Due to the high risk of relapse and overdose after tapering, this practice is not recommended by clinical guidelines, however, clients may still request to taper off medication. The ideal time to initiate an OAT taper is not known. However, ethically, taper plans should acknowledge clients' preferences and autonomy but apply principles of shared informed decision-making regarding safety and efficacy...
April 29, 2024: BMJ Open